CN113728008A - 抗cd40抗体及其用途 - Google Patents

抗cd40抗体及其用途 Download PDF

Info

Publication number
CN113728008A
CN113728008A CN202080027681.4A CN202080027681A CN113728008A CN 113728008 A CN113728008 A CN 113728008A CN 202080027681 A CN202080027681 A CN 202080027681A CN 113728008 A CN113728008 A CN 113728008A
Authority
CN
China
Prior art keywords
seq
amino acid
antibody
cells
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080027681.4A
Other languages
English (en)
Other versions
CN113728008B (zh
Inventor
张宏恺
王媛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nankai University
Original Assignee
Nankai University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nankai University filed Critical Nankai University
Publication of CN113728008A publication Critical patent/CN113728008A/zh
Application granted granted Critical
Publication of CN113728008B publication Critical patent/CN113728008B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

提供了特异性结合CD40的新型抗体和抗体片段以及含有所述抗体或抗体片段的组合物、药物、组合产品和试剂盒。此外，还提供了编码所述抗体或其抗体片段的核酸及包含其的宿主细胞，以及相关用途。此外，还提供了这些抗体和抗体片段的治疗和诊断用途。

Description

PCT国内申请，说明书已公开。

Claims (22)

  1. PCT国内申请，权利要求书已公开。
CN202080027681.4A 2019-04-10 2020-04-10 抗cd40抗体及其用途 Active CN113728008B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201910284441 2019-04-10
CN2019102844411 2019-04-10
CN202010262466 2020-04-03
CN2020102624664 2020-04-03
PCT/CN2020/084186 WO2020207470A1 (zh) 2019-04-10 2020-04-10 抗cd40抗体及其用途

Publications (2)

Publication Number Publication Date
CN113728008A true CN113728008A (zh) 2021-11-30
CN113728008B CN113728008B (zh) 2024-04-09

Family

ID=72752143

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080027681.4A Active CN113728008B (zh) 2019-04-10 2020-04-10 抗cd40抗体及其用途

Country Status (9)

Country Link
US (1) US20220324988A1 (zh)
EP (1) EP3954705A4 (zh)
JP (1) JP2022527406A (zh)
CN (1) CN113728008B (zh)
AU (1) AU2020256828A1 (zh)
CA (1) CA3136491A1 (zh)
SG (1) SG11202111188VA (zh)
TW (1) TW202103733A (zh)
WO (1) WO2020207470A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023236951A1 (zh) * 2022-06-06 2023-12-14 普米斯生物技术(珠海)有限公司 抗cd40抗体及其用途

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102373590B1 (ko) * 2020-09-22 2022-03-14 (주)아이엠지티 음이온성 고분자를 이용한 신규한 나노 입자, 이의 제조 방법 및 조성물
CN113444178B (zh) * 2021-06-17 2022-12-02 南京蓝盾生物科技有限公司 抗cd70内化的抗体、抗体偶联物及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103635488A (zh) * 2011-04-29 2014-03-12 埃派斯进有限公司 抗-cd40抗体及其使用方法
US20170088624A1 (en) * 2015-09-30 2017-03-30 Janssen Biotech, Inc. Agonistic Antibodies Specifically Binding CD40 and Methods of Use
WO2017205742A1 (en) * 2016-05-27 2017-11-30 Abbvie Biotherapeutics Inc. Anti-cd40 antibodies and their uses
CN109069621A (zh) * 2015-09-04 2018-12-21 普里玛托普医疗股份有限公司 人源化抗-cd40抗体及其用途
CN109265552A (zh) * 2012-10-30 2019-01-25 埃派斯进有限公司 抗-cd40抗体及其使用方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US6326482B1 (en) 1999-04-23 2001-12-04 Genentech, Inc. SH2 domain-containing peptides
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
WO2005092925A2 (en) 2004-03-24 2005-10-06 Xencor, Inc. Immunoglobulin variants outside the fc region
ES2579805T3 (es) 2004-09-23 2016-08-16 Genentech, Inc. Anticuerpos y conjugados modificados por ingeniería genética con cisteína
GB201308658D0 (en) 2013-05-14 2013-06-26 Isis Innovation Antibodies
CN107709365A (zh) * 2015-04-13 2018-02-16 戊瑞治疗有限公司 癌症组合疗法
BR112017023646A2 (pt) 2015-05-04 2018-07-17 Apogenix Ag proteínas agonistas de receptor de cd40 de cadeia simples
PE20180315A1 (es) 2015-06-29 2018-02-09 Bristol Myers Squibb Co Anticuerpos para cd40
US10479838B2 (en) * 2015-06-29 2019-11-19 Bristol-Myers Squibb Company Antibodies to CD40 with enhanced agonist activity
EP3470424A4 (en) * 2016-06-08 2020-03-04 Shanghai Jiaotong University School of Medicine SEQUENCE OF HEAVY CHAIN CONSTANT ANTIBODY REGION TO INCREASE AGONIST-ANTIBODY ACTIVITY

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103635488A (zh) * 2011-04-29 2014-03-12 埃派斯进有限公司 抗-cd40抗体及其使用方法
CN109265552A (zh) * 2012-10-30 2019-01-25 埃派斯进有限公司 抗-cd40抗体及其使用方法
CN109069621A (zh) * 2015-09-04 2018-12-21 普里玛托普医疗股份有限公司 人源化抗-cd40抗体及其用途
US20170088624A1 (en) * 2015-09-30 2017-03-30 Janssen Biotech, Inc. Agonistic Antibodies Specifically Binding CD40 and Methods of Use
WO2017205742A1 (en) * 2016-05-27 2017-11-30 Abbvie Biotherapeutics Inc. Anti-cd40 antibodies and their uses
CN109476750A (zh) * 2016-05-27 2019-03-15 艾伯维生物制药股份有限公司 抗cd40抗体及其用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LIU，Y.H.等: "High-throughput reformatting of phagedisplayed antibody fragments to IgGs by onestep emulsion PCR" *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023236951A1 (zh) * 2022-06-06 2023-12-14 普米斯生物技术(珠海)有限公司 抗cd40抗体及其用途

Also Published As

Publication number Publication date
EP3954705A1 (en) 2022-02-16
SG11202111188VA (en) 2021-11-29
JP2022527406A (ja) 2022-06-01
CA3136491A1 (en) 2020-10-15
TW202103733A (zh) 2021-02-01
AU2020256828A1 (en) 2021-11-18
EP3954705A4 (en) 2023-06-07
CN113728008B (zh) 2024-04-09
WO2020207470A1 (zh) 2020-10-15
US20220324988A1 (en) 2022-10-13

Similar Documents

Publication Publication Date Title
US10273307B2 (en) Humanized anti-CD134 (OX40) antibodies and uses thereof
KR102384845B1 (ko) 항-pd-l1 항체 및 그의 용도
JP6883579B2 (ja) 新規抗ｐｄ−１抗体
TWI652345B (zh) 與４-１ｂｂ結合之分子類
KR20190039421A (ko) 항-tigit 항체, 항-pvrig 항체 및 이들의 조합
AU2019310803A1 (en) Anti-TIGIT antibody and uses thereof
EP3409689A1 (en) Anti-cd134 (ox40) antibodies and uses thereof
US11732044B2 (en) Anti-LAG-3 antibody and use thereof
CN111196852A (zh) 抗tigit抗体及其用途
KR20160110995A (ko) Pd-1에 대한 항체 분자 및 그의 용도
CN113728008B (zh) 抗cd40抗体及其用途
KR20230093010A (ko) 신규 항-lilrb2 항체 및 유도체 생성물
WO2019129137A1 (zh) 抗lag-3抗体及其用途
WO2022187710A1 (en) Epha2 antibodies
CN116829588A (zh) 新型抗lilrb2抗体和衍生产物
KR20230156727A (ko) 항-vsig4 항체 또는 이의 항원 결합 단편 및 용도
EA044486B1 (ru) Трехкомпонентные комбинированные препараты антител
AU2014202213A1 (en) Binding Molecules to the Human OX40 Receptor

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40060290

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant